The purpose of this study is to determine the effects, good and bad, of injecting chemotherapy into recurrent laryngeal squamous cell carcinoma (SCC) tumors.

Start Date01 Sep 2026

Sponsor / Collaborator

University of Miami

NCT07620327

/ Not yet recruitingPhase 4IIT

Effect of Push-Dose Adrenaline on Peri-intubation Cardiovascular and Clinical Outcomes During Rapid Sequence Intubation in the Emergency Department: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial

Rapid sequence intubation is commonly performed in the emergency department to secure the airway of critically ill patients. However, blood pressure may decrease during or shortly after intubation because of the patient's underlying illness, the effects of induction medications, and the transition to positive-pressure ventilation. This complication is known as peri-intubation hypotension and is associated with worse clinical outcomes.
This study will evaluate whether a preemptive low dose of intravenous adrenaline, also known as epinephrine, can reduce peri-intubation hypotension in adult emergency department patients undergoing rapid sequence intubation. Participants will be randomly assigned to receive either 10 mcg of intravenous adrenaline or 1 mL of 0.9% sodium chloride placebo immediately before induction. The study will compare hemodynamic changes, vasopressor requirements, safety outcomes, and mortality between the two groups.

Start Date01 Jun 2026

Sponsor / Collaborator-

CTR20260950

/ CompletedNot Applicable

肾上腺素鼻喷雾剂在健康研究参与者中随机、开放、两制剂、单次给药、两周期、交叉设计的生物等效性预试验

[Translation] A preliminary bioequivalence study of epinephrine nasal spray in healthy study participants using a randomized, open-label, two-formulation, single-dose, two-period, crossover design.

主要目的：以石药集团欧意药业有限公司生产的肾上腺素鼻喷雾剂为受试制剂，以ARS PHARMACEUTICALS OPERATIONS INC持证的肾上腺素鼻喷雾剂（商品名：Neffy®）为参比制剂，按生物等效性试验的有关规定，考察两制剂的人体生物等效性，为正式生物等效性试验提供依据。次要目的：观察受试制剂肾上腺素鼻喷雾剂和参比制剂肾上腺素鼻喷雾剂（商品名：Neffy®）在健康参与者中的安全性。

[Translation]

Primary Objective: To investigate the human bioequivalence of the two formulations, using epinephrine nasal spray manufactured by CSPC Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. as the test formulation and epinephrine nasal spray (trade name: Neffy®) certified by ARS PHARMACEUTICALS OPERATIONS INC. as the reference formulation, in accordance with the relevant regulations for bioequivalence studies, and to provide a basis for formal bioequivalence trials. Secondary Objective: To observe the safety of the test formulation, epinephrine nasal spray, and the reference formulation, epinephrine nasal spray (trade name: Neffy®), in healthy participants.

Start Date29 Mar 2026

Sponsor / Collaborator

CSPC Ouyi Pharmaceutical Co., Ltd.

100 Clinical Results associated with Adrenaline

100 Translational Medicine associated with Adrenaline

100 Patents (Medical) associated with Adrenaline

34,379

Literatures (Medical) associated with Adrenaline

01 Dec 2026·Journal of Cardiovascular Translational Research

Ventricle-Specific Biomechanical Responses to Inotropic and Vasoactive Drugs in Human Myocardial Slices

Article

Author: Meuwese, Christiaan L ; Bogers, Ad J J C ; Amesz, Jorik H ; Taverne, Yannick J H J ; Manintveld, Olivier C ; Langmuur, Sanne J J ; de Groot, Natasja M S ; Veen, Kevin M ; Alipour Symakani, Rahi S

Abstract:

This study aimed to compare baseline biomechanical contractile properties between right (RV) and left ventricular (LV) human living myocardial slices (LMS) and explore the effect of dobutamine, noradrenaline, adrenaline, levosimendan and enoximone in both ventricles. Sixty-three slices (33 RV, 30 LV) were produced from 5 explanted hearts. At baseline, RV LMS had a higher maximum contraction force, shorter contraction duration, time to peak and time to relaxation, steeper dF/dt and a larger peak area than LV LMS. Dobutamine administration had a larger effect in RV than LV LMS. Spontaneous, irregular contractions were observed after noradrenaline, adrenaline and dobutamine administration. In conclusion, RV LMS showed a stronger contraction with higher contraction velocity as compared to LV LMS and exhibited a greater response to dobutamine. These findings contribute to the understanding of the RV physiology as a separate entity, advocating for a different approach in treating RV or LV dysfunction.Graphical Abstract

01 Jul 2026·AMERICAN HEART JOURNAL

Design and rationale of a multicenter paramedic randomized trial of noradrenaline versus adrenaline in the initial management of patients with cardiogenic shock—The PANDA trial

Article

Author: Salathiel, Ross ; Palmer, Sonny ; Chew, Derek P ; Percival, Mia ; Voskoboinik, Aleksandr ; Dawson, Luke P ; Bloom, Jason E ; Batchelor, Riley ; Boggett, Stuart ; Pilcher, David ; Meadley, Ben ; Okyere, Daniel ; Hartshorne, Trent ; Stub, Dion ; McManamny, Tegwyn ; Nehme, Ziad ; Kaye, David M ; Ball, Jocasta ; Anderson, David ; Nelson, Adam J ; Reid, Christopher

BACKGROUND:

Vasoactive medications constitute an integral component of the hemodynamic support strategy in patients with cardiogenic shock (CS). However, there is an emerging signal of harm associated with the commonly used catecholamine, epinephrine (adrenaline), when used in the treatment of CS. The PAramedic randomized trial of Noradrenaline (norepinephrine) versus Adrenaline in the management of patients with cardiogenic shock (PANDA) was therefore designed to determine if the initial treatment with norepinephrine, compared with epinephrine, improves outcomes in patients with CS.

METHODS AND DESIGN:

The PANDA trial is a prehospital, open-label, single-blind, randomized controlled trial designed to assess the efficacy and safety of two commonly used catecholaminergic agents, norepinephrine and epinephrine, in the initial resuscitation of patients with suspected CS. Patients aged 18 years and older are eligible for recruitment by paramedics if there is clinical evidence of hypoperfusion, a measured systolic blood pressure of ≤90 mmHg despite adequate volume resuscitation with intravenous fluids, and the shock etiology is of a suspected cardiac cause (including cardiac arrest of an estimated duration of less than 30-minutes). Paramedics will randomize an anticipated 1,155 patients over an estimated 5-year period in a 1:1 ratio to receive an infusion of epinephrine or norepinephrine, which will be titrated to achieve a target systolic blood pressure of 100 mmHg. The primary efficacy outcome will be all-cause 28-day mortality. Recruitment commenced on February 28, 2024 and a total of 450 patients have been recruited thus far.

IMPLICATIONS:

The PANDA trial will determine if norepinephrine, compared to epinephrine, for the initial hemodynamic support in CS improves outcomes. The results will help inform future treatment recommendations for the management of patients with CS.

TRIAL REGISTRATION:

ACTRN12621000805875.

01 Jul 2026·The journal of allergy and clinical immunology. Global

Predicting outcomes of hazelnut oral food challenge: Pediatric cohort analysis

Article

Author: Röst, Angela ; Boucq, Camille ; Breiding, Maria ; Trück, Johannes ; Höfer, Veronika ; Maurer, Jacqueline ; Kuhn, Alena

Background:

Hazelnut is a common trigger of IgE-mediated food allergy in children, but clinical tolerance remains difficult to predict. While molecular diagnostics and guideline-based cutoffs offer valuable insights, their real-world applicability across heterogeneous populations is uncertain.

Objective:

Predictors of outcomes in pediatric hazelnut oral food challenges (OFCs) were evaluated to assess the diagnostic utility of clinical risk assessment and molecular markers.

Methods:

We conducted a single-center cohort study of 190 OFCs performed between 2022 and 2025. Clinical indication, prechallenge risk classification, laboratory markers, and predefined cofactors were prospectively documented. Outcomes were stratified by tolerance and intolerance. Predictive values for Cor a 14, hazelnut-specific IgE, skin prick test, and physician risk assessment were analyzed. Common thresholds and European Academy of Allergy and Clinical Immunology cutoffs were used.

Results:

Overall, 56% of OFCs were tolerated and 44% resulted in confirmed allergy. Cor a 14 ≥ 0.64 kU_A/L was the most accurate serologic predictor of intolerance (positive predictive value 88%, sensitivity 92%, specificity 90%), particularly in high-risk subgroups. Clinical high-risk classification predicted intolerance with a positive predictive value of 85%. Conversely, Cor a 14 < 0.64 kU_A/L and low-risk classification were associated with tolerance (positive predictive value, 93% and 89%, respectively). Age under 5 years, no prior reactions, and no adrenaline prescription further supported tolerance. OFCs enabled therapy optimization and avoided unnecessary oral immunotherapy in 13% of high-risk patients.

Conclusion:

Cor a 14 and physician risk assessment reliably predict hazelnut OFC outcomes and guide personalized care. OFCs remain essential for diagnostic clarification and shared decision-making in pediatric allergy practice.

444

News (Medical) associated with Adrenaline

09 Jun 2026

·www.biospace.com

Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)

Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Pro Intravenous Ondansetron in Animal Study; Program to Advance to First-in-Human PK Study in Third Quarter of 2026 TEL AVIV, Israel, June 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive results from a preclinical pharmacokinetic (“PK”) and safety study of NS003, the Company’s proprietary intranasal powder formulation of ondansetron being developed for chemotherapy and post-operative nausea and vomiting. Ondansetron is one of the most widely used therapies for chemotherapy-induced nausea and vomiting. In 2023, more than 12 million prescriptions were dispensed to over 6 million patients. Zofran (ondansetron) peak sales exceeded $1.5 billion. The study compared NS003 to the intravenous (“IV”) formulation in an animal study. Data showed that NS003 had a PK pro to IV, with similar time to maximum concentration (Tmax) and area under the curve (AUC) results. In a separate toxicology study, NS003 demonstrated a favorable safety pro four times the test dose, with no adverse effects observed. With this milestone achieved, Nasus Pharma is now preparing to initiate a first-in-human PK study in the third quarter of 2026. “These results represent a significant milestone for our pipeline programs as well as a further demonstration of the potential of our Nasax platform,” said Dan Teleman, Chief Executive Officer of Nasus Pharma. “Approximately 1 million patients in the United States receive chemotherapy annually, 60–80% of whom undergo highly or moderately emetogenic regimens, while an additional 800,000 patients undergo radiotherapy each year, with more than half experiencing radiotherapy-induced nausea and vomiting. Our market research indicates that 15–20% of these patients experience breakthrough nausea and vomiting not adequately controlled by oral therapies, often requiring a return to the clinic for intravenous anti-emetic treatment. Intranasal administration of NS003 has the potential to address this unmet need by offering a convenient, fast-onset alternative that may reduce avoidable clinic visits. We look forward to advancing NS003 to a first-in-human trial during the third quarter of 2026, followed by the pivotal study of NS002 for anaphylaxis in the fourth quarter of 2026, supporting the continued expansion of our intranasal product portfolio.” About Nasus Pharma Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma’s proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit or follow on Twitter (X) or LinkedIn. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward-looking statements in this press release when it discusses: the planned initiation and timing of a first-in-human PK study and trial for NS003, the timing of the NS002 pivotal study, expected clinical and development milestones, and the expansion of the Company’s product portfolio. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 25, 2026. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Corporate Contact Nasus Pharma Ltd. Israel info@nasuspharma.com Investor s Contact Mike Moyer LifeSci Advisors +1-617-308-4306 mmoyer@lifesciadvisors.com

04 Jun 2026

·www.biospace.com

ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company ALK will present data and key insights within anaphylaxis, food and respiratory allergy. At two ALK symposia, FlashTalk, oral and poster sessions at the EAACI 2026 scientific programme, ALK will present data on real-world use and clinical implementation of nasal adrenaline in anaphylaxis and share key learnings from 20 years of experience with SLIT tablets. The two symposia will take place as follows: Friday 12 June, 12:00-13:00 : From evidence to practice: Real-world use and clinical implementation of nasal adrenaline in anaphylaxis. The symposium will address the unmet needs in paediatric and adult anaphylaxis management, the role of nasal adrenaline, including a presentation of real-world use, patient preference and clinical implementation. Saturday 13 June, 12:00-13:00 : 20 years of SQ SLIT-tablet experience: Key learnings and new horizons The symposium will address the disease modifying and preventative benefits of allergy immunotherapy, the clinical benefits beyond allergic rhinitis and share efficacy and safety outcomes of a peanut SLIT-tablet phase I/II trial. Simon Lawton, Global Medical Affairs, Chief medical Office at ALK says: “We are looking forward to contributing to this year’s EAACI congress where we will showcase the important innovation under way at ALK across anaphylaxis and food allergy. We will also share key insights grounded in robust science and 20 years’ experience with SLIT-tablets. We hope that many EAACI attendees will join our symposia.” In total, ALK has contributed to 29 abstracts in the scientific programme. Of particular note are additional efficacy and safety findings from clinical trials in adults and children with allergic rhinitis/rhino conjunctivitis treated with SLIT-tablets. Key highlights of ALK’s contribution include: Therapy area Abstract title Lead author Abstract Number/ Presentation Details Anaphylaxis Patient Preferences for Nasal Adrenaline Spray versus Adrenaline Auto-Injectors in Anaphylaxis: A Multi-Country Discrete Choice Experiment Worm M #001368 Thematic poster session Sunday 14 June 2026, 12:15-13:15 Anaphylaxis Healthcare Professionals’ Perspectives on Anaphylaxis Management: A Multi-Country Survey comparing Adrenaline Auto-Injectors and Nasal Adrenaline Sprays Fox A #001283 Flash talks session Saturday 13 June 2026, 16:45-18:15 Anaphylaxis Intranasal Adrenaline Associated with Lower Administration-Related Anxiety and Higher Willingness to Use Versus Adrenaline Auto-Injectors Mack D #000889 Flash talks session Saturday 13 June 2026, 16:45-18:15 Anaphylaxis Comparative Ease-of-Use Assessment of a Nasal Adrenaline Spray with an Adrenaline Auto-Injector in Children, Adults and Caregivers Mack D #000890 Flash talks session Saturday 13 June 2026, 16:45-18:15 Respiratory allergy Effect of SQ SLIT-tablets on asthma symptoms and safety in children with allergic rhinitis and with or without concomitant asthma across multiple trials Pfaar O #000781 Oral presentation Sunday 14 June 2026, 08:45 - 10:15 Respiratory allergy Symptom control and reduced intranasal corticosteroid use in children with allergic rhinitis/rhinoconjunctivitis treated with SQ house dust mite SLIT-tablet: A responder analysis Pfaar O #000815 Flash talks session Sunday 14 June 2026, 12:15-13:15 Respiratory allergy Reduction in symptom and medication scores in the first week of the first pollen season in children and adults treated with SQ SLIT-tablets across phase III trials Durham S #100185 Flash talks session Sunday 14th June 2026, 12:15 – 13:15 Real-world evidence Long-term real-world effectiveness of allergen immunotherapy on respiratory infections in children and adults with allergic rhinitis and asthma Woehlk C #000748 Flash talks session Friday 12 June 2026, 12:00-13:00 Real-world evidence Effectiveness of sublingual immunotherapy (SLIT) tablets on dispensed asthma medications and treatment regimens: Results from the Real-world Evidence of aLlergy immunotherapY (RELY) study Woehlk C #000751 Oral presentation Saturday 13 June 2026, 13:15-14:45 Real-world evidence Long-term effectiveness of HDM SLIT-tablets on symptom-relieving prescriptions: Results from the Japanese register-based study, Real-world Evidence of house dust Mite sublingual Immunotherapy Tablets (REMIT) Durham S #001258 Oral presentation Saturday 13 June 2026, 13:15-14:45 For further information, please contact : Investor Relations : Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALK ALK is a global specialty pharmaceutical company focused on allergy. ALK's activities cover the entire value chain of developing, sourcing, producing, and marketing a diversified portfolio of products for diagnosing and treating respiratory allergies and severe allergic reactions (anaphylaxis) in both children and adults. Headquartered in Denmark, ALK employs around 2,700 people worldwide and is listed on Nasdaq Copenhagen (Nasdaq: ALK B). Visit us at . Attachment Press Release_ALK at EAACI 2026_final

ImmunotherapyPhase 3

01 Jun 2026

·www.biospace.com

Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis

TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that it will host a virtual key opinion leader (“KOL”) event on Wednesday, June 10, 2026 at 8:00 AM ET featuring Michael S. Blaiss, MD (Medical College of Georgia, Good Samaritan Health Center of Gwinnett) and Joel Brooks, DO, MPH (Columbia University Vagelos College of Physicians and Surgeons, New York-Presbyterian Morgan Stanley Children’s Hospital), who will join members of the Company’s management to discuss the unmet need and current treatment landscape for anaphylaxis. To register, click here . The event will provide an overview of Nasus Pharma and NS002, the Company’s epinephrine intranasal powder candidate in development for the treatment of anaphylaxis. The current standard of care for anaphylaxis is the EpiPen ® injection. KOLs will review NS002’s Phase 2 data, which shows faster and higher absorption than EpiPen ® , demonstrating that NS002 is poised to potentially transform the epinephrine landscape. They will also discuss the challenges faced by pediatric patients and the perspectives of practicing physicians on the need for needle-free epinephrine. A live question and answer session will follow the formal presentations. About Michael S. Blaiss, MD Michael S. Blaiss, MD, is a clinical professor of pediatrics, division of allergy/immunology at Medical College of Georgia in Augusta, Georgia, and allergist at Good Samaritan Health Center of Gwinnett in Norcross, Georgia. He received his BS in Zoology at the University of Georgia, where he was in Phi Beta Kappa and his medical degree from the University of Tennessee Center for Health Sciences where he was inducted into AOA Honor Society. He did a pediatrics residence at University of Tennessee/Le Bonheur Children’s Medical Center in Memphis and completed a fellowship in allergy/immunology at Ochsner Medical Foundation in New Orleans, Louisiana. He is past president of the American College of Allergy, Asthma and Immunology. He served as treasurer of the American Board of Allergy and Clinical Immunology, a past member of the Board of Directors of the World Allergy Organization and past president of the Tennessee and Louisiana Societies of Allergy, Asthma and Immunology. He was Executive Medical Director of the American College of Allergy, Asthma, and Immunology. In addition, he has been a member of the editorial boards for the Annals of Allergy, Asthma, and Immunology, World Allergy Organization Journal, Journal of Asthma and Allergy and Asthma Proceedings, Hypersensitivity, and American Journal of Rhinology and Allergy. Dr. Blaiss has published over 200 peer-reviewed scientific articles in the field of allergy and presented at more than 500 meetings and seminars throughout the world. About Joel Brooks, DO, MPH Joel Brooks, DO, MPH, is an Assistant Professor of Pediatrics at the Columbia University Vagelos College of Physicians and Surgeons and an Attending Pediatrician in the Division of Allergy, Immunology, and Rheumatology at New York-Presbyterian Morgan Stanley Children’s Hospital. Dr. Brooks completed his medical degree at the Chicago College of Osteopathic Medicine, followed by an Internal Medicine Residency and Chief Residency at UPMC Lititz Hospital. He then pursued Allergy and Immunology Fellowship training at the Yale School of Medicine, during which he earned a Master of Public Health in global health and social and behavioral sciences from the Yale School of Public Health. He also completed the Fellows as Medical Educators Certificate Program at Yale. After fellowship, Dr. Brooks joined the faculty at Children’s National Hospital in Washington, DC, where he served as a staff allergist and Assistant Professor of Pediatrics at the George Washington University School of Medicine and Health Sciences. He also served as Site Director for the National Institute of Allergy and Infectious Diseases Allergy and Immunology Fellowship Program. Dr. Brooks’s clinical and research interests include anaphylaxis, food allergy, drug allergy, and angioedema. He has presented his work at national and international conferences and published in multiple peer-reviewed journals. He is also deeply committed to medical education and serves on several committees within both the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology. About Nasus Pharma Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma’s intranasal powder epinephrine product candidate is being developed as a needle-free alternative to epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma’s proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit or follow on Twitter (X) or LinkedIn . Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward looking statements in this press release when it discusses: the potential of NS002 as a needle-free treatment for anaphylaxis; that NS002 is poised to potentially transform the epinephrine landscape; and the potential benefits of the Company’s proprietary intranasal technology. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 25, 2026. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Company Contact Nasus Pharma Ltd. info@nasuspharma.com Investor Contact Mike Moyer LifeSci Advisors +1-617-308-4306 mmoyer@lifesciadvisors.com

100 Deals associated with Adrenaline

External Link

KEGG	Wiki	ATC	Drug Bank
D00095	Adrenaline	C01CA24 B02BC09 S01EA01	DB00668

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Intermittent asthma	United States	Armstrong Pharmaceuticals, Inc.	07 Nov 2018
Mydriasis	United States	Ph Healthcare Services	07 Dec 2012
Hypersensitivity	United States	Viatris Specialty LLC	22 Dec 1987
Anesthesia	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Bronchial Spasm	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Hemorrhage	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Hypotension	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Shock	Japan	Daiichi Sankyo Co., Ltd.	25 Feb 1986
Anaphylaxis	China	Grand Pharmaceutical Group	01 Jan 1981
Heart Arrest	China	Grand Pharmaceutical Group	01 Jan 1981
Asthma	United States	Wyeth Consumer Healthcare LLC	08 Nov 1967

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Rhinitis, Allergic	Phase 2	Canada	Nasus Pharma Ltd.	03 Nov 2025
Rhinitis, Allergic, Seasonal	Phase 2	Canada	Nasus Pharma Ltd.	03 Nov 2025
Persistent asthma	Phase 2	United States	ARS Pharmaceuticals, Inc.	28 Jul 2022
Urticaria	Phase 2	United States	ARS Pharmaceuticals, Inc.	28 Jul 2022
Hypersensitivity, Immediate	Phase 2	Canada	Aquestive Therapeutics, Inc.	12 Jul 2022
Drug Hypersensitivity	Phase 1	Sweden	Orexo AB	22 Apr 2024
Respiratory Tract Infections	Phase 1	Australia	ARS Pharmaceuticals, Inc.	09 Aug 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00678145 (CTgov)	Phase 2	Hypoglycemia \| Pure Autonomic Failure \| Diabetes Mellitus	39	Morphine Sulfate (Morphine Sulfate)	mbkdjauoip(npvvedcdrw) = cepuvawtvs gmlccbtpxw (aqmqtvpzpl, 0.18) View more	-	19 May 2026
				Morphine Sulfate (Matched Placebo (Saline for Morphine Sulfate))	mbkdjauoip(npvvedcdrw) = lrnknandrs gmlccbtpxw (aqmqtvpzpl, 0.33) View more
NCT03913845 (Retropubic Lidocaine vs Saline, CTgov)	Phase 4	Urinary Incontinence, Stress \| Urinary Retention	150	Epinephrine+Lidocaine (Lidocaine + Epinephrine)	usnypfuskg = lwzwscvewp obokgsvthc (hakzfatdxk, pepfyapazk - wrfureivgp) View more	-	30 Apr 2026
				Epinephrine+Saline (Saline + Epinephrine)	usnypfuskg = wouxzhqgye obokgsvthc (hakzfatdxk, vaiaszoppc - mbmzjyqxmo) View more
Company_Website Manual	Phase 2	Rhinitis, Allergic	50	NS002	gbgcegguaa(ejmulugeer) = flfkewwhpg asqridfzlf (dkhfzvgzrf ) View more	Positive	16 Mar 2026
				EpiPen	gbgcegguaa(ejmulugeer) = niqzuakres asqridfzlf (dkhfzvgzrf ) View more
NCT05488847 (CTgov)	Phase 4	Shoulder Pain \| Periarthritis scapulohumeralis	83	pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Non Opioid, Multimodal Protocol)	mebyoinhpi(zdprunbocj) = ryfaqgowiy eoyjpgdunt (yucewnnotw, 1.7)	-	10 Feb 2026
				pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Opioid Protocol)	mebyoinhpi(zdprunbocj) = zjirgaevdh eoyjpgdunt (yucewnnotw, 1.6) View more
NCT04032119 (Pubmed \| Gastrointest Endosc)	Phase 3	Gastric mucosal lesion	774	1:100,000 diluted epinephrine-added injection solution	towhazoyaf(oiltmrosfq) = ryawcrgjns oesndzmkoe (fgbcptdljl, 46.0)	Positive	01 Jan 2026
				Normal injection solution	towhazoyaf(oiltmrosfq) = manofkotxc oesndzmkoe (fgbcptdljl, 45.0)
NCT02722746 (Pilot epinephrine dose-finding study, CTgov)	Phase 1/2	Analgesia \| Hypotension	66	Ropivacaine (Ropivacaine Only Control Group)	yiqtgnlluo: percent difference = 20.8 (95% CI, -8.9 to 47.3), P-Value = 0.165	-	18 Jun 2025
				Ropivacaine+Epinephrine (Ropivacaine + 2 mcg/mL Epinephrine)
CTIS2024-514037-38-00 (OX640-002, Company_Website) Manual	Not Applicable	Rhinitis, Allergic	30	OX640	yvtvanjkzb(uwxjeixadv) = Topline data analysis demonstrates that OX640 treatments achieved mean epinephrine plasma levels associated with clinical efficacy more rapidly than the intramuscular injection, with dose-dependent exposure levels. pvkiaxzwzb (ifvlcdiitc ) View more	Positive	10 Jan 2025
				0.3 mg intramuscular epinephrine
GlobeNewswire Manual	Not Applicable	Oral allergy syndrome	-	Anaphylm (with allergen exposure)	qlimpxuhbd(rnpcjuyzok) = no significant differences found between Anaphylm PK results in subjects with and without allergen exposure. odormokrli (hdmtopnzhv ) Met View more	Positive	24 Oct 2024
				Anaphylm (without allergen exposure)
NCT04207840 (Pubmed \| J Aerosol Med Pulm Drug Deliv)	Phase 4	Asthma \| Anaphylaxis	28	Epinephrine MDI	hzmzhplbga(ysvnetygoi) = ifoleoveks kvdpkxarwx (gsnnlunkcz )	Positive	29 Aug 2024
				Epinephrine IM	hzmzhplbga(ysvnetygoi) = qcbnsccwtz kvdpkxarwx (gsnnlunkcz )
NCT03126968 (PROPHET, CTgov)	Phase 2/3	Hemorrhage \| Lung transplant rejection \| Hemoptysis	66	Topical epinephrine (Prophylactic Topical Epinephrine)	ndplpvxevv = cdqddacelr wcmnqryvtw (fldnjbvdfy, ypuuxuoffg - swjoacfghd) View more	-	28 Aug 2024
				Placebos (Placebo)	ndplpvxevv = smyidbofff wcmnqryvtw (fldnjbvdfy, jkyywldnry - ehhulwktlm) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis